JNJ Johnson & Johnson
- Official Name: JOHNSON & JOHNSON
- Headquarters: One Johnson & Johnson Plaza, NEW BRUNSWICK, NJ, 08933 US
- CEO: Joaquin Duato
- Website: jnj.com
- Key Investor: VANGUARD GROUP INC | 9.72%
- Dedicated Investor: ROBERT WOOD JOHNSON FOUNDATION | 87.12%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-16 | 1 | Won by 4.341 TOTW | 4.824 - 0.483 | ||
| 2025-07-23 | 2 | Won by 4.924 | 5.366 - 0.442 | ||
| 2025-07-29 | 2R | Won by 3.641 | 2.329 - (1.312) | ||
| 2025-07-30 | 3 | Lost by 0.842 | (2.105) - (1.263) | ||
| 2025-08-06 | 4 | Won by 3.762 | 1.963 - (1.799) | ||
| 2025-08-07 | 1R | Won by 3.007 | 0.614 - (2.393) | ||
| 2025-08-12 | 3R | Lost by 2.389 | (0.453) - 1.936 | ||
| 2025-08-13 | 5 | Won by 0.847 | 2.590 - 1.743 | ||
| 2025-08-20 | 6 | Won by 3.910 | 2.416 - (1.494) | ||
| 2025-08-21 | 2R | Won by 1.794 | 1.364 - (0.430) | ||
| 2025-08-27 | 7 | Won by 2.957 | (1.309) - (4.266) | ||
| 2025-09-03 | 8 | Won by 5.750 | 0.712 - (5.038) | ||
| 2025-09-04 | 3R | Won by 0.099 | 0.456 - 0.357 | ||
| 2025-09-10 | 9 | Lost by 2.623 | (1.256) - 1.367 | ||
| 2025-09-11 | 4R | Lost by 0.212 | 1.572 - 1.784 | ||
| 2025-09-17 | 10 | Won by 5.920 | 0.860 - (5.060) | ||
| 2025-09-17 | 1R | Won by 0.065 | 0.400 - 0.335 | ||
| 2025-09-24 | 11 | Lost by 1.104 | (0.291) - 0.813 | ||
| 2025-10-01 | 12 | Won by 4.348 TOTW | 5.285 - 0.937 | ||
| 2025-10-01 | QF | Won by 2.833 | 0.333 - (2.500) | ||
| 2025-10-08 | 13 | Won by 3.686 | 1.933 - (1.753) | ||
| 2025-10-15 | 14 | Won by 1.620 | 0.750 - (0.870) | ||
| 2025-10-15 | SF | Won by 0.868 | 0.176 - (0.692) | ||
| 2025-10-22 | 15 | Won by 1.173 | 0.863 - (0.310) | ||
| 2025-10-22 | F | Lost by 2.165 | 0.547 - 2.712 |
Latest News
Yahoo - 2025-11-24
If You Invested $10K In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?
Johnson & Johnson (NYSE:JNJ) is a global healthcare company that develops, manufactures, and sells pharmaceutical products and medical devices. It...
Yahoo - 2025-11-24
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalt...
Yahoo - 2025-11-24
BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study
Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.
Yahoo - 2025-11-24
EXCLUSIVE: Sustainable Value Creation: Keynote Fireside with Trian Fund Management, 5th Palm Beach CorpGov Forum
CorpGov and IPO Edge are pleased to provide complete video coverage of the fifth annual Palm Beach CorpGov Forum held on Nov. 5-6, featuring keynote s...
Yahoo - 2025-11-24
Hip Replacement Market Competitive Landscape Report 2025: Recent Developments, Strategies, Sustainability, Product Launches, Key Persons, and Revenue Forecasts
The Hip Replacement industry is poised for substantial growth, projected to reach US$ 10.24 billion by 2033, up from US$ 6.92 billion in 2024, at a CA...
Yahoo - 2025-11-24
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
It has grown wildly, and it could keep growing.
Yahoo - 2025-11-24
RVL Pharmaceuticals Announces Leadership Appointments to Accelerate Next Phase of Growth and Commercial Momentum
RVL Pharmaceuticals, Inc and its affiliates (together, "RVL") today announced a series of senior leadership appointments to strengthen the o...
SeekingAlpha - 2025-11-23
Tracking Bridgewater Associates 13F Portfolio - Q3 2025 Update
Get a 2025 update on Bridgewater Associatesâ $25.53B portfolio, top stock moves, and diversification strategies.
Yahoo - 2025-11-23
Jim Cramer Dissects Kimberly-Clark’s Acquisition of Kenvue
Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently offered insights on. Cramer discussed the company’s planned acquisi...
SeekingAlpha - 2025-11-22
Near-Perfect Portfolio Strategy For Today's Uncertain Market
Read about our "Near-Perfect" Strategy portfolio for steady income, growth, and lower risk.
Yahoo - 2025-11-22
Jim Cramer on Kenvue: “I Think It is a Good Situation, Not a Bad One”
Kenvue Inc. (NYSE:KVUE) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if long-term shareholders sh...
Yahoo - 2025-11-21
How Recent Developments Are Rewriting the Story for Johnson & Johnson
Johnson & Johnson's stock narrative has seen a notable development, with the consensus analyst price target rising slightly from $199.56 to $...
SeekingAlpha - 2025-11-21
Dividend Champion, Contender, And Challenger Highlights: Week Of November 30
See here for latest weekly updates on dividend changes, ex-dividend dates, and pay dates for Dividend Champions, Contenders, and Challengers.
Yahoo - 2025-11-21
Contineum’s MS drug falls short in Phase II trial
Despite PIPE-307’s failure in RRMS, analysts still have hope for the candidate in major depressive disorder (MDD).
Yahoo - 2025-11-21
1 Reason Why Shares of Johnson & Johnson Are Surging This Month
A spate of promising news is helping to extend a post-earnings rally for the healthcare giant's shares.
Yahoo - 2025-11-21
Eli Lilly Reaches $1 Trillion Market Cap on Booming Weight-Loss Drugs
Lilly becomes the first pharmaceutical company to hit that threshold, joining a select club of mostly tech companies.
Yahoo - 2025-11-21
Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI
LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.
Yahoo - 2025-11-21
This Medical Technology Leader Sees Profit Growth Topping 44%
The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.
Yahoo - 2025-11-21
Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It?
HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.
Yahoo - 2025-11-21
Surgical Stapling Devices Market Analysis Report 2025: Disposable Surgical Stapling Devices Lead Expansion Amid Rising Demand for Minimally Invasive Procedures - Global Forecast to 2029
The global surgical stapling devices market, valued at $5.23 billion in 2023, is anticipated to grow to $8.32 billion by 2029, with a CAGR of approxim...
CNBC - 2025-11-20
Friday's big stock stories: What’s likely to move the market in the next trading session
Stocks fell on Thursday after a volatile session that saw a more than 1,000-point reversal on the Dow and a more than 2% drop in the Nasdaq.
Show more
Yahoo - 2025-11-20
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
Yahoo - 2025-11-20
OMP Miami Conference 2025: Transforming Supply Chain Vision into REAL Impact with Human-AI Synergy
Yahoo - 2025-11-20
Clarity Eye Centre Brings SILK™ Laser Eye Technology to Hong Kong
Yahoo - 2025-11-19
Sector Update: Health Care Stocks Softer Late Afternoon
Yahoo - 2025-11-19
Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
Yahoo - 2025-11-19
Why Johnson & Johnson's Share Price Is Popping This Month
Yahoo - 2025-11-19
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
SeekingAlpha - 2025-11-19
Pfizer: Is This Pharma Giant Finally A Bargain
MarketWatch - 2025-11-19
Dow's nearly 125-point rally led by gains for shares of NVIDIA Corp., Cisco
Yahoo - 2025-11-19
Why GRAIL Stock Could Be Biotech’s Next Big Breakout
SeekingAlpha - 2025-11-19
Zymeworks: A Lot Of Moving Parts
Yahoo - 2025-11-19
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?
Yahoo - 2025-11-19
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Yahoo - 2025-11-19
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
Yahoo - 2025-11-19
Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?
MarketWatch - 2025-11-19
Why biotech and drug stocks are rallying even though the rest of the market is hurting
SeekingAlpha - 2025-11-19
Why VYM Is Not A Good Alternative To SCHD
Yahoo - 2025-11-18
Why Johnson & Johnson (JNJ) Is Up 5.9% After Multiple FDA Approvals and Positive Drug Trial Results
SeekingAlpha - 2025-11-18
Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2025 Update
Yahoo - 2025-11-18
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
Yahoo - 2025-11-18
3 Smart Defensive Stocks for an Uneasy Market
Yahoo - 2025-11-18
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
CNBC - 2025-11-18
How to use the tax-loss selling occurring now to pick up quality stocks on the cheap
SeekingAlpha - 2025-11-18
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?
Yahoo - 2025-11-18
Johnson & Johnson to acquire Halda Therapeutics for $3.05bn
Yahoo - 2025-11-17
Stock Market Today: Dow Wobbles As Nvidia Slides; Google Jumps On Warren Buffett Stake (Live Coverage)
Yahoo - 2025-11-17
Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment
Yahoo - 2025-11-17
Top Midday Stories: Amazon to Sell Used Ford Vehicles on Website; Novo Nordisk Cuts Wegovy, Ozempic Prices
Yahoo - 2025-11-17
Correction: Johnson & Johnson Strikes $3.05 Billion Deal to Buy Cancer Drug Developer Halda
Yahoo - 2025-11-17
J&J to acquire Halda, Sinclair takes 8.2% stake in E.W. Scripps
Yahoo - 2025-11-17
Johnson & Johnson Strikes $3.05 Deal to Buy Cancer Drug Developer Halda
Yahoo - 2025-11-17
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
Yahoo - 2025-11-17
Take the Zacks Approach to Beat the Markets: Macy's, United Natural Foods & Monster Beverage in Focus
Yahoo - 2025-11-17
Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion
SeekingAlpha - 2025-11-17
Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Yahoo - 2025-11-17
Halda Therapeutics Announces Acquisition by Johnson & Johnson
Yahoo - 2025-11-17
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
Yahoo - 2025-11-17
J&J adds to pharma’s M&A spree with $3B buyout of startup Halda
Yahoo - 2025-11-17
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
CNBC - 2025-11-17
The Club's top 10 things to watch in the stock market Monday
Yahoo - 2025-11-14
Sector Update: Health Care Stocks Ease Late Afternoon
Yahoo - 2025-11-14
US Equity Indexes Mixed Amid Technology Rebound
Yahoo - 2025-11-14
US Equity Indexes Mixed as Technology Rebound Helps Lift Nasdaq, S&P 500
Yahoo - 2025-11-14
How Recent Moves Are Rewriting the Story for Pfizer
Yahoo - 2025-11-14
Bristol Myers Shares Sink on Yet Another Trial Failure
Yahoo - 2025-11-14
Top Stock Movers Now: StubHub, DoorDash, Netflix, and More
Yahoo - 2025-11-14
US Equity Indexes Mixed in Midday Trading
Yahoo - 2025-11-14
Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail
Yahoo - 2025-11-14
Jim Cramer on Amgen: “Why Not Go Buy That?”
Yahoo - 2025-11-14
Sector Update: Health Care Stocks Decline Premarket Friday
Yahoo - 2025-11-14
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
Yahoo - 2025-11-14
Update on Phase 3 Librexia ACS Trial
SeekingAlpha - 2025-11-14
Merck's Cidara Buyout Is An Opportunistic Win For Both Parties - Here's Why
Yahoo - 2025-11-13
Jim Cramer Shows Confidence in Amgen
Yahoo - 2025-11-13
Jim Cramer Praises Johnson & Johnson (JNJ)’s Drugs
Yahoo - 2025-11-13
Why Is Johnson & Johnson (JNJ) Up 1.7% Since Last Earnings Report?
Yahoo - 2025-11-13
Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
Yahoo - 2025-11-13
2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon
Yahoo - 2025-11-13
2 Strong Healthcare Stock Picks for Dividend Investors
Yahoo - 2025-11-12
Walt Disney and 15 More Non-AI Stocks Worth a Look
Yahoo - 2025-11-12
Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
Yahoo - 2025-11-12
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
Yahoo - 2025-11-12
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Yahoo - 2025-11-12
'Michael Burry Scared Me,' Says 25-Year-Old Who Bought Nvidia Dip For $101—'SOLD IT ALL!!' Over AI Bubble Fears, Now Sitting On Cash Awaiting Crash
SeekingAlpha - 2025-11-12
MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential
Yahoo - 2025-11-12
J&J's MedTech Unit Sales Improve: Will the Momentum Last?
Yahoo - 2025-11-12
Assessing Johnson & Johnson's Value After Medtech Acquisition and 34.6% Year-to-Date Surge
MarketWatch - 2025-11-12
Healthcare breakout means investors should add exposure to the sector, says Strategas
Yahoo - 2025-11-11
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know
Yahoo - 2025-11-11
Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know
Yahoo - 2025-11-11
Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know
Yahoo - 2025-11-11
Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know
Yahoo - 2025-11-11
Elevance Health, Labcorp, Privia Health, Fortrea, and Amgen Shares Are Soaring, What You Need To Know
Yahoo - 2025-11-11
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know
Yahoo - 2025-11-11
Inspire Medical Systems, UFP Technologies, Astrana Health, Option Care Health, and The Pennant Group Shares Skyrocket, What You Need To Know
Yahoo - 2025-11-11
Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know
CNBC - 2025-11-11
There could be a buying opportunity in consumer packaged goods stocks, Jim Cramer says
Yahoo - 2025-11-11
A Look at Johnson & Johnson’s Valuation Following Back-to-Back FDA Approvals for Oncology and Neuropsychiatry Therapies
CNBC - 2025-11-11
Dow rallies 300 points to new record with shutdown set to end Wednesday: Live updates
SeekingAlpha - 2025-11-11
Medtronic: Possible Earnings Beat Incoming But Still Overvalued
MarketWatch - 2025-11-11
Dow rallies 500 points on gains in Nike, Merck shares
SeekingAlpha - 2025-11-11
Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript
SeekingAlpha - 2025-11-11
Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
MarketWatch - 2025-11-11
Nike, Merck share gains lead Dow's 386-point climb
MarketWatch - 2025-11-11
Dow rallies nearly 250 points on gains in shares of Merck, Nike
SeekingAlpha - 2025-11-11
Globus Medical: Straightening Its Back
CNBC - 2025-11-10
Nasdaq falls as tech shares come under pressure again; S&P 500 is little changed: Live updates
Yahoo - 2025-11-10
Black Hair Accessories Brand Targets $50M Revenue By 2030 With New Products, Market Expansion
SeekingAlpha - 2025-11-10
Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating
Yahoo - 2025-11-09
Jim Cramer Says Haleon’s “Stock’s Been Struggling”
Yahoo - 2025-11-07
Jim Cramer Says He “Believed in” Bristol-Myers’ Cobenfy But “It’s Not Selling Well at All”
Yahoo - 2025-11-07
Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships?
Yahoo - 2025-11-07
J&J’s Darzalex gains first FDA approval in smouldering multiple myeloma
Yahoo - 2025-11-07
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
SeekingAlpha - 2025-11-07
Johnson & Johnson: Dividends Don't Lie
Yahoo - 2025-11-06
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
Yahoo - 2025-11-06
J&J’s Caplyta wins MDD approval to extend revenue horizon
Yahoo - 2025-11-06
AstraZeneca to pour $50bn into US ahead of New York listing as UK investment plans stall
Yahoo - 2025-11-06
AstraZeneca CEO bullish on record revenue numbers and US growth
Yahoo - 2025-11-06
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
Yahoo - 2025-11-06
J&J brain drug acquired in $14.6B buyout cleared for broader use
CNBC - 2025-11-06
Cramer's Mad Dash: Johnson & Johnson
Yahoo - 2025-11-06
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe
SeekingAlpha - 2025-11-05
The Play On The Cooper Companies
SeekingAlpha - 2025-11-05
November's Dog Of The Dow Ideal "Safer" Buy: Verizon
Yahoo - 2025-11-05
Jim Cramer Just Couldn’t Help Himself When Talking About Kimberly-Clark (KMB)’s Kenvue Acquisition
SeekingAlpha - 2025-11-04
Tracking AMG's Yacktman Asset Management Portfolio - Q3 2025 Update
Yahoo - 2025-11-04
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
Yahoo - 2025-11-04
Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn
Yahoo - 2025-11-04
Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal
Yahoo - 2025-11-04
Will Pipeline Milestones and New Oral Therapies Shift Johnson & Johnson's (JNJ) Growth Narrative?
CNBC - 2025-11-04
Palantir earnings, Pizza Hut's options, a new consumer staples giant and more in Morning Squawk
Yahoo - 2025-11-04
Tulyp Medical Emerges From Sofinnova’s Medtech Accelerator and Announces FDA Submission Following Initial First-in-Human Use
Yahoo - 2025-11-04
Alvotech faces FDA setback for its Simponi biosimilar AVT05
Yahoo - 2025-11-03
Kimberly-Clark Stock Takes Biggest One-Day Hit Since Black Monday
Yahoo - 2025-11-03
BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors
Yahoo - 2025-11-03
Is the End of the Line Near for Kenvue?
Yahoo - 2025-11-03
Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger
Yahoo - 2025-11-03
Kimberly-Clark bets $40 billion on Kenvue despite Tylenol controversy
Yahoo - 2025-11-03
Kimberly-Clark to Buy Kenvue in $48.7 Billion Deal
Yahoo - 2025-11-03
Tylenol trust crisis: Trump, RFK Jr. and Texas lawsuits slam Kenvue
Yahoo - 2025-11-03
Kimberly-Clark Stock Heads for Biggest One-Day Drop Since Black Monday
MarketWatch - 2025-11-03
Kimberly-Clark to Buy Tylenol Maker Kenvue. Why the Stock Market Hates the Deal.
Yahoo - 2025-11-03
Why Tylenol Maker Kenvue Stock Just Popped
Yahoo - 2025-11-03
Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger
SeekingAlpha - 2025-11-03
Alvotech: Initiating With Hold Rating On FDA CRL AVT05 And Reduced EBITDA Guidance
Yahoo - 2025-11-03
Kimberly-Clark buys Tylenol maker Kenvue for more than $48 billion
Yahoo - 2025-11-03
Kimberly-Clark Strikes $40 Billion Deal for Tylenol Maker Kenvue
Yahoo - 2025-11-03
Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal
Yahoo - 2025-11-03
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Yahoo - 2025-11-03
Kimberly-Clark to Acquire Kenvue
Yahoo - 2025-11-03
Japan Non-Invasive Aesthetic Treatment Market Analysis and Outlook 2025-2033 with City-Level Breakdowns by Procedure, Gender and End User
MarketWatch - 2025-11-03
Tylenol maker Kenvue leads S&P 500, boosted by $48.7 billion Kimberly-Clark deal
Yahoo - 2025-11-03
Johnson & Johnson Stock: Is Wall Street Bullish or Bearish?
CNBC - 2025-11-03
Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal, creating consumer staples giant
SeekingAlpha - 2025-11-02
American Century Equity Income Fund Q3 2025 Key Contributors/Detractors And Notable Trades
SeekingAlpha - 2025-11-01
Best Dividend Aristocrats For November 2025
Yahoo - 2025-10-31
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
Yahoo - 2025-10-31
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
Yahoo - 2025-10-31
Appointment of Yves Decadt as Member of Poxel’s Board of Directors
Yahoo - 2025-10-31
I’m 65, itching to retire but only have $500K saved. I want $2K/month plus my Social Security — how can I swing this?
SeekingAlpha - 2025-10-31
AbbVie: Why Q3 Confirms Its Immunology Dominance
Yahoo - 2025-10-31
The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage
Yahoo - 2025-10-30
Top Analyst Reports for Broadcom, Johnson & Johnson and Palantir
Yahoo - 2025-10-30
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Yahoo - 2025-10-30
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
Yahoo - 2025-10-30
Is Ulta Beauty's (ULTA) CFO Appointment a Signal for Change Amid Margin and Demand Concerns?
DowJones - 2025-10-29
Ken Paxton Bellies Up to the Trial Bar
Yahoo - 2025-10-29
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
SeekingAlpha - 2025-10-29
Best Dividend Kings: October 2025
Fintel - 2025-10-28
Johnson & Johnson (JNJ) Price Target Increased by 10.96% to 204.02
Yahoo - 2025-10-28
Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results
Yahoo - 2025-10-28
Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson
Yahoo - 2025-10-28
Is Johnson & Johnson’s Share Price Justified After Recent Surge in 2025?
Yahoo - 2025-10-28
Texas Suit Accuses Tylenol Maker of Hiding a Link to Autism
Yahoo - 2025-10-28
Tylenol Is Tied to Autism, Texas Claims in Suit. Kenvue Stock Shudders.
Yahoo - 2025-10-28
H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90
Yahoo - 2025-10-28
Texas sues Kenvue and J&J, Truth Social to offer prediction markets
Yahoo - 2025-10-28
As Dow Hits Record, High-Yield Dogs of the Dow Still a Bargain
Yahoo - 2025-10-28
Update: Texas AG Sues Kenvue, Johnson & Johnson for Alleged Deceptive Marketing of Tylenol to Pregnant Women
SeekingAlpha - 2025-10-28
The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products
Yahoo - 2025-10-28
ISRG Rides on da Vinci 5 Momentum: Can This Growth Sustain?
Yahoo - 2025-10-28
2 Dividend Stocks to Double Up on Right Now
Yahoo - 2025-10-28
Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?
Yahoo - 2025-10-27
Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?
Yahoo - 2025-10-27
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Yahoo - 2025-10-27
3 Healthcare Stocks to Buy Hand Over Fist in October
Yahoo - 2025-10-27
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Yahoo - 2025-10-27
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
Yahoo - 2025-10-27
Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial
Yahoo - 2025-10-27
Johnson and Johnson to spin off orthopaedics market
Yahoo - 2025-10-27
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
Yahoo - 2025-10-27
Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal
Yahoo - 2025-10-27
3 Healthcare Stocks Paying the Highest Dividends of 2025
SeekingAlpha - 2025-10-26
Dividend Income: Bert's September Dividend Income Summary
Yahoo - 2025-10-26
3 Dividend Stocks With Yields Over 5%. Should You Buy?
Yahoo - 2025-10-26
Meet all 37 White House ballroom donors funding the $300 million build, including Silicon Valley tech giants, crypto bros and the Lutnicks
Yahoo - 2025-10-26
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.
Yahoo - 2025-10-25
Johnson & Johnson (JNJ): Evaluating Valuation After Recent Share Gains and Growth Outlook
Yahoo - 2025-10-24